ECTRIMS-ACTRIMS 2023: Cladribine Has Low Annualized Risk for Relapse for Patients With Relapsing-Remitting Multiple Sclerosis
However, cladribine may not be as effective as natalizumab, ocrelizumab, alemtuzumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.